姓 名：杜适
职称职务：博士，青年特聘教授
电子邮箱：dushi@suda.edu.cn
个人简介
杜适，国际创新药学院青年特聘教授。本科和硕士毕业于中国药科大学（药剂学），后于美国俄亥俄州立大学药学院取得药物科学博士学位。回国前任职于美国纽约西奈山伊坎医学院（Icahn School of Medicine at Mount Sinai）访问学者，美国俄亥俄州立大学医学院生物医学信息系博士后研究员。主要从事核酸药物递送、mRNA治疗和生物信息学辅助药物设计研究。近五年以第一作者或通讯作者在Nature Nanotechnology （IF 38.1）、Advanced Materials（IF 32）、Advanced Science(IF 14.8)、Journal of Controlled Release（IF 10.5）等国际主流期刊发表13篇SCI论文，引用1200余次，H-因子16。作为共同发明人在美申报3项发明专利，授权1项国内专利。
研究方向
1、脂质纳米颗粒(LNPs)等新型生物材料的开发
2、细胞特异性和多功能药物递送系统的开发。
3、核酸药物靶向递送与基因治疗
4、人工智能驱动新一代药物设计
代表性论文（#代表第一作者，*代表通讯作者）
1.Liu, Y., Qi, Y., Chen, C., Jin, Y., Du, S.*, Qiao, J.*, & Yao, J.* (2023). Platelet-mimetic nano-sensor for combating postoperative recurrence and wound infection of triple-negative breast cancer. Journal of Controlled Release, 362, 396-408.
2.Lv, S., Liu, Y., Xie, C., Xue, C., Du, S.*, & Yao, J.* (2023). Emerging role of interactions between tumor angiogenesis and cancer stem cells. Journal of Controlled Release, 360, 468-481.
3.Zhang, Y.#, Hou, X.#, Du, S.#, Xue, Y., Yan, J., Kang, D.D., ... & Dong, Y. (2023). Close the cancer–immunity cycle by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy. Nature Nanotechnology, 18(11), 1364-1374.
4.Du, S.#, Yan, J., Xue, Y., Zhong, Y., & Dong, Y. (2023). Adoptive cell therapy for cancer treatment. Exploration, 3(4), 20210058.
5.Du, S.#, Li, W., Zhang, Y., Xue, Y., Hou, X., Yan, J., ... & Dong, Y. (2023). Cholesterol‐Amino‐Phosphate (CAP) Derived Lipid Nanoparticles for Delivery of Self‐Amplifying RNA and Restoration of Spermatogenesis in Infertile Mice. Advancedscience,10(11), 2300188.
6.Zhong, Y.#, Du, S.#, & Dong, Y. (2023). mRNA delivery in cancer immunotherapy. Acta Pharmaceutica Sinica B, 13(4), 1348-1357.
7.Du, S.#, Cheng, J., & Dong, Y. (2023). Nanomaterials for Therapeutic Nucleic Acid Delivery. Handbook of Chemical Biology of Nucleic Acids (pp. 1-29). Singapore: Springer Nature Singapore.
8.Yan, J.#, Zhang, Y.#, Du, S.#, Hou, X., Li, W., Zeng, C., ... & Dong, Y. (2022). Nanomaterials-mediated co-stimulation of toll-like receptors and CD40 for antitumor immunity. Advanced Materials, 34(47), 2207486.
9.Du, S.#, Xiong, H., & Yao, J. (2021). Redox-Responsive Nanomedicine. Stimuli-Responsive Nanomedicine, 99-132.
10.Chan, C.#, Du, S.#, Dong, Y., & Cheng, X. (2021). Computational and experimental approaches to investigate lipid nanoparticles as drug and gene delivery systems. Current topics in medicinal chemistry, 21(2), 92-114.
11.Du, S.#, Yu, Y., Xu, C., Xiong, H., Yang, S., & Yao, J. (2019). LMWH and its derivativesrepresentnewrationalfor cancer therapy: construction strategies and combination therapy. Drugdiscoverytoday, 24(10), 2096-2104.
12.Du, S.#, Xiong, H., Xu, C., Lu, Y., & Yao, J. (2019). Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines. Biomaterials science, 7(3), 1147-1160.